Anti-papillomavirus vaccines and prevention of cervical cancer: Progress and prospects;Vaccins anti-papillomavirus et prévention du cancer du col de l'utérus: Avancées et perspectives

Presse Medicale

Volumn 34, Issue 10, 2005, Pages 745-753

  Hantz, Sébastien ^b   Alain, Sophie ^b   Denis, François ^a  

^a DUPUYTREN UNIVERSITY HOSPITAL   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BIVALENT VIRUS LIKE PARTICLE L1 VACCINE; CAPSID PROTEIN; CAPSID PROTEIN L1; PAPILLOMA VIRUS VACCINE; QUADRIVALENT HUMAN PAPILLOMA VIRUS LIKE PARTICLE L1 VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; CLINICAL TRIAL; CONDYLOMA; DRUG EFFICACY; DRUG TOLERABILITY; EXPERIMENTAL INFECTION; FEMALE; GENITAL TRACT INFECTION; GENOTYPE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; ONCOGENE; PAPILLOMA VIRUS; REVIEW; SKIN DEFECT; UTERINE CERVIX CANCER; UTERINE CERVIX CYTOLOGY; VACCINATION; VIRUS ASSEMBLY; VIRUS CARCINOGENESIS; VIRUS INFECTION; VIRUS PARTICLE;

EID: 20944443595     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0755-4982(05)84030-8     Document Type: Review

References (62)

1. El Mrini T, Arveux P, Gay C. Estimation du coût de traitement du cancer du col de l'utérus. Rev Epidemiol Santé 1997; 45: 508-15.
2. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J et al. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995; 87: 796-802.
3. Schreckenberger C, Kaufmann AM. Vaccination strategies for the treatment and prevention of cervical cancer. Curr Opin Oncol 2004; 16: 485-91.
4. Abma JC, Sonenstein FL. Sexual activity and contraceptive practices among teenagers in the United States, 1988 and 1995. Vital Health Stat 2001; 23: 1-79.
5. Connor N, Catchpole M, Rogers PA, Macdonald N, Mc Garrigle C, Simms I et al. Sexually transmitted diseases among teenagers in England and Wales. Commun Dis Rep CDR Review 1997; 7: R173-8.
6. Bozon M. À quel âge les femmes et les hommes commencent-ils leur vie sexuelle? Comparaison mondiale et évolution récente. Population et Sociétés 2003; 391: 1-4.
7. Boulanger JC, Sevestre H, Bauville E, Ghighi C, Harlicot JP, Gondry J. Epidėmiologie de l'infection à HPV. Gynecol Obstet Fertíl 2004; 32: 218-23.
8. Bosch FX. Epidėmiologie des infections à HPV de type muqueux. In: Papillomavirus humains. Biologie et pathologie tumorale. Aubin F, Prétet JL, Mougin C eds. Editions Tec & Doc, Paris, 2003; 335-57.
9. Moscicki AB, Shiboski S, Hills NK, Powell KJ, Jay N, Hanson EN et al. Regression of low-grade squamous intra-epithelial lesions in young women. Lancet 2004; 364: 1678-83.
10. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189: 12-9.
11. Exbrayat C. Col de l'utérus. In: Evolution de l'incidence et de la mortalité par cancer en France de 1978 à 2000. Remontet L, Buemi A, Velten M, Jougla E, Estève J eds. Institut de Veille Sanitaire, Paris, 2003; 107-12.
12. Petry KU. HPV in gynecology: association with CIN and cervical cancer. International congress of sexually transmitted infections of the ISSTDR & IUSTI, Berlin, 24-27 juin 2001.
13. Miller K, Blumenthal P, Blanchard K. Oral contraceptives and cervical cancer: critique of a recent review. Contraception 2004; 69: 347-51.
14. Deacon JM, Evans CD, Yule R, Desai M, Binns W, Taylor C et al. Sexual behaviour and smoking as determinants of cervical HPV infection and of CIN3 among those infected: a case-control study nested within the Manchester cohort. Br J Cancer 2000; 83: 1565-72.
15. Xi LF, Carter JJ, Galloway DA, Kuypers J, Hughes JP, Lee SK et al. Acquisition and natural history of human papillomavirus type 16 variant infection among a cohort of female university students. Cancer Epidemiol Biomarkers Prev 2002; 11: 343-51.
16. Beby-Defaux A, Agius G. Papillomaviridae. In: Traité de virologie médicale. Huraux JM, Nicolas JC, Agut H, Peigue-Lafeuille H eds. Estern, Paris, 2003; 267-73.
17. Douvier S, Dalac S. Infections à papillomavirus. Encycl Méd Chir, Maladies infectieuses 2004; 8-054-A-10, 19 p.
18. Bousarghin L, Touzé A, Sizaret PY, Coursaget P. Fixation, internalisation et trafic cellulaire des papillomavirus. In: Papillomavirus humains. Biologie et pathologie tumorale. Aubin F, Prétet JL, Mougin C eds. Editions Tec & Doc, Paris 2003; 25-34.
19. Dalstein V, Prétet JL, Mougin C. Histoire naturelle de l'infection à HPV muqueux. In: Papillomavirus humains. Biologie et pathologie tumorale. Aubin F, Prétet JL, Mougin C eds. Editions Tec & Doc, Paris 2003; 287-307.
20. Delvenne P, Hubert P, Havard L, Renard I, Boniver J, Jacobs N. Modèles expérimentaux in vitro des HPV. In: Papillomavirus humains. Biologie et pathologie tumorale. Aubin F, Pretet JL, Mougin C eds. Editions Tec & Doc, Paris 2003; 77-101.
21. th edition. Knipe DM, Howley PM eds. Editions Lioppincott Williams & Wilkins, Philadelphia 2001; 2231-64.
22. Koutsky LA, Holmes KK, Critchlow CW, Stevens CE, Paavonen J, Beckmann AM et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 1272-8.
23. Woodman CB, Collins S, Winter H, Bailey A, Ellis J, Prior P et al. Natural history of cervical human papillomavirus infection in young women: a longitudinal cohort study. Lancet 2001; 357: 1831-6.
24. Collot-Teixeira S, Bass J, Denis F, Ranger-Rogez S. Human tumor suppressor p53 and DNA viruses. Rev Med Virol 2004; 14: 301-19.
25. Jones DL, Munger K. Interactions of the human papillomavirus E7 protein with cell cycle regulators. Semin Cancer Biol 1996; 7: 327-37.
26. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, Kiviat N et al. Comparison of human papillomavirus types 16,18 and 6 capsid antibody responses following incident infection. J Infect Dis 2000; 181: 1911-19.
27. Mestecky J, Russel MW. Induction of mucosal immune responses in the human genital tract. FEMS Immunol Med Microbiol 2000; 27: 351-5.
28. Silins I, Avall-Lundqvist E, Tadesse A, Jansen KU, Stendahl U, Lenner P et al. Evaluation of antibodies to human papillomavirus as pronostic markers in cervical cancer patients. Gynecol Oncol 2002; 85: 333-8.
29. Nicholls PK, Moore PF, Anderson DM, Moore RA, Parry NR, Gough GW et al. Regression of canine oral papillomas is associated with infiltration of CD4+ and CD8+ lymphocytes. Virology 2001; 283: 31-9.
30. Höpfl R, Heim K, Christensen N, Zumbach K, Wieland U, Volgger B et al. Spontaneous regression of CIN and delayed-type hypersensitivity to HPV-16 oncoprotein E7. Lancet 2000; 356: 1985-6.
31. Frazer IH. Prevention of cervical cancer through papillomavirus vaccination. Nature 2004; 4: 46-54.
32. Scott M, Nakagawa M, Moscicki AB. Cell-mediated immune response to human papillomavirus infection. Clin Diag Lab Immunol 2001; 8: 209-20.
33. Bouvet JP. Immunité des muqueuses. In: Immunité et infection. Concepts immunopathologiques et perspectives thérapeutiques. Mege JL, Revillard JP, Raoult D eds. Arnette, Paris, 1997; 27-38.
34. Chang MH, Chen Q, Lai MS, Hsu HM, Wu TC, Kong MS et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. New Engl J Med 1997; 336: 1855-9.
35. Rickinson AB, Kieff E. Epstein-Barr Virus, chapter 75. In: Fields, Virology, 4th edition. Knipe DM, Howley PM eds. Lippincott Williams & Wilkins, Philadelphia, 2001; 2575-627.
36. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D et al. Against which human papilomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
37. e édition. Plotkin SA, Orenstein WA eds. Elsevier, Philadelphia 2004; 1259-65.
38. Hagensee M, Yaegashi N, Galloway D. Self-assembly of human papillomavirus type 1 capsids by expression of the L1 protein alone or by coexpression of the L1 and L2 capsid proteins. J Virol 1993; 67: 315-22.
39. Rose RC, Reichmann RC, Bonnez W. Human papillomavirus (HPV) type 11 recombinant virus-like particles induce the formation of neutralizing antibodies and detect HPV-specific antibodies in human sera. J Gen Virol 1994; 75: 2075-9.
40. Schiller JT, Lowy DR. Papillomavirus-like-particles and HPV vaccine development. Semin Cancer Biol 1996; 7: 373-82.
41. Breitburd F, Kirnbauer R, Hubbert NL, Nonnenmacher B, Trin-Dinh-Desmarquet C, Orth G et al. Immunization with viruslike particles from cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995; 69: 3959-63.
42. Suzich JA, Ghim SJ, Palmer-Hill FJ, White WI, Tamura JK, Bell JA et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. Proc Natl Acad Sci USA 1995; 92: 11553-7.
43. McDermott MR, Bienenstock J. Evidence for a common mucosal immunologic system. Migration of B immunoblasts into intestinal, respiratory, and genital tissues. J Immunol 1979; 122: 1892-8.
44. Lowe RS, Brown DR, Bryan JT, Cook JC, George HA, Hofmann KJ et al. Human papillomavirus type 11 (HPV-11) neutralizing antibodies in the serum and genital mucosal secretions of African green monkeys immunized with HPV-11 virus-like particles expressed in yeast. J Infect Dis 1997; 176: 1141-5.
45. Rose RC, Lane C, Wilson S, Suzich JA, Rybicki E, Williamson AL. Oral vaccination of mice with human papillomavirus virus-like particles induces systemic virus-neutralizing antibodies. Vaccine 1999; 17: 2129-35.
46. Balmelli C, Roden R, Potts A, Schiller J, De Grandi P, Nardelli-Haefliger D. Nasal immunization of mice with human papillomavirus type 16 virus-like particles elicits neutralizing antibodies in mucosal secretions. J Virol 1998; 72: 8220-9.
47. Dupuy C, Buzoni-Gatel D, Touze A, Bout D, Coursaget P. Nasal immunization of mice with human papillomavirus type 16 (HPV-16) virus-like particles or with the HPV-16 L1 gene elicits specific cytotoxic T lymphocytes in vaginal draining lymph nodes. J Virol 1999; 73: 9063-71.
48. Roden RB, Ling M, Wu TC. Vaccination to prevent and treat cervical cancer. Hum Pathol 2004; 35: 971-82.
49. Evans TG, Bonnez W, Rose RC, Koenig S, Demeter L, Suzich JA et al. A Phase 1 study of a recombinant viruslike particle vaccine against human papillomavirus type 11 in healthy adult volunteers. J Infect Dis 2001; 183: 1485-93.
50. Harro CD, Pang YY, Roden RB, Hildesheim A, Wang Z, Reynolds MJ et al. Safety and immunogenicity trial in adult volunteers of a human papillomavirus 16 L1 virus-like particle vaccine. J Natl Cancer Inst 2001; 93: 284-92.
51. Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347: 1645-51.
52. Brown DR, Bryan JT, Schroeder JM, Robinson TS, Fife KH, Wheeler CM et al. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer. J Infect Dis 2001; 184: 1183-6.
53. Villa L, Costa R, Petta C, Andrade R, Ault KA, Giuliano AR et al. A dose-ranging safety and immunogenicity study of a quadrivalent HPV (types 6/11/16/18) L1 VLP vaccine in women. 20th International Papillomavirus Conference, Paris, 4-9 octobre 2002. Abstract O 099.
54. Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A et al. Efficacity of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004; 364: 1757-65.
55. Mao C, Koutsky L, Ault K, Wheeler C, Brown DM, Wiley D et al. Prophylactic human papillomavirus (HPV) 16 virus like particle prevents HPV 16-related cervical intraepithelial neoplasia 2-3. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington DC, 2004. Abstract G-1675a.
56. Pinto LA, Edwards J, Castle PE, Harro CD, Lowy DR, Schiller JT et al. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis 2003; 188: 327-38.
57. Brown DR, Fife KH, Wheeler CM, Koutsky LA, Lupinacci LM, Railkar R et al. Early assessment of the efficacy of a human papillomavirus type 16 L1 virus-like particle vaccine. Vaccine 2004; 22: 2936-42.
58. Schiffman M, Castle PE. Human papillomavirus: epidemiology and public health. Arch Pathol Lab Med 2003; 127: 930-4.
59. Hawes SE, Critchlow CW, Faye Niang MA, Diouf MB, Diop A, Toure P et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188: 555-63.
60. Nardelli-Haefliger D, Wirthmer D, Schiller JT, Lowy DR, Hildesheim A, Ponci F et al. Specific antibody levels at tha cervix during the menstrual cycle of women vaccinated with human papillomavirus 16 Virus-like particles. J Natl Cancer Inst 2003; 95: 1128-37.
61. Lowy DR, Frazer IH. Prophylactic human papillomavirus vaccine. J Natl Cancer Inst Monogr 2003; 31: 111-16.
62. Schiller JT, Davies P. Delivering on the promise: HPV vaccines and cervical cancer. Nature Rev 2004; 2, 343-7.